KU Leuven

Situated in Belgium, in the heart of Western Europe, KU Leuven has been a centre of learning for nearly six centuries. Today, it is Belgium’s largest university and, founded in 1425, one of the oldest and most renowned universities in Europe.

As a leading European research university and co-founder of the League of European Research Universities (LERU), KU Leuven offers a wide variety of international master’s programmes, all supported by high-quality, innovative, interdisciplinary research. Since its founding, KU Leuven has been based in the city that shares its name. Leuven is a pleasant, safe and bustling student town, where centuries-rich history meets cutting-edge science. The university also offers degree programmes at campuses in 11 Belgian cities, including Brussels, Ghent and Antwerp.

Role of institution in the project

KU Leuven is involved in the WP3, on Ethical, Legal, and Social Issues (ELSI).

Dr. Janos Meszaros

Janos Meszaros is a postdoctoral researcher at the KU Leuven's Faculty of Pharmaceutical Sciences and at the Centre for IT & IP Law (CiTiP) since 2021. His research focuses on data protection, AI, and medical law, with particular attention to the legal framework of clinical trials and digital healthcare. Janos holds a PhD from the University of Szeged in data protection. He worked at a law firm for two years, focusing on IT and tax law. From 2017 to 2021, he worked at the National Academy of Science in Taiwan as a postdoctoral researcher on the legal aspects of biobanking and AI in healthcare.

Prof. Isabelle Huys

Prof. Isabelle Huys is a pharmacist, with further specialization in toxicology (PhD), and legal/regulatory aspects (LLM Munich). She has experience in pharmaceutical as well as legal and regulatory aspects along the drug life cycle. Most of her research is performed in collaboration with diverse stakeholders (academics, industry, clinicians, regulators, HTA, payers, performing qualitative as well as quantitative research. Isabelle Huys heads a research group of about 10 PhDs in regulatory sciences, most of them in collaboration with stakeholders in the field of drug development as well as in the field of biobanking and data sharing.

Join the EUCAIM Consortium

Open Call for New Beneficiaries

We’re inviting new partners to enhance our pan-European infrastructure for cancer images and artificial intelligence.

Whether you’re a data holder with valuable cancer images or an innovator developing AI tools for precision medicine, this is your chance to contribute to a groundbreaking project.

Apply by 10 June 2024!

Open Call Webinar

We recently hosted a webinar with more details for prospective applicants to the open call. A recording is available.

Our open Call for new collaborators
launches in April 2024

Opportunities for data holders & AI developers to contribute await! Let‘s join forces to enhance cancer diagnosis and treatment

Be the first to know and apply!

March 14, 10:00-11:30 aM CET



Explore the potential for AI-driven cancer care advancements!
Learn how to access and utilize our federated cancer image repository. The webinar is for AI Innovators & Data Providers interested in the platform and will feature an introduction to EUCAIM & Cancer Image Europe and a demonstration of data exploration & access.

Survey Invitation

Join Leading Experts In Shaping AI In Cancer

EUCAIM is looking for your feedback! We have recently published a Stakeholder Survey in order to reach out to potential end-users and stakeholders. We believe that your insights could significantly contribute to understanding the expectations of potential users and identifying the essential aspects that stakeholders find crucial for future engagement and collaboration with the platform.

Therefore, we would like to invite you to participate in the Stakeholder Survey about the Cancer Image Europe platform.

Completing the survey will take approximately 10 minutes. Your participation is crucial to the success of this project, and we deeply appreciate your expertise in shaping the future of cancer imaging and treatment.